Nu Holdings is trading at its most interesting inflection point in months — a stock up 13% in thirty days, with analysts freshly divided and options hedging climbing even as the lending market stays wide open.
The analyst picture tells a tale of two camps. JP Morgan raised its target to $20 on July 7, maintaining Overweight, and Needham initiated at Buy with a $17 target in late June — both votes of confidence in Nu's Latin American growth runway. But those constructive calls followed a rougher stretch: Citigroup downgraded to Neutral in mid-June, cutting its target from $18 to $13, and Bank of America went further, moving to Underperform with a $10 target in early June. The consensus mean price target sits at $17.93, implying roughly 25% upside from the current $14.39 close. That gap is real, but the spread between the bull ($20) and bear ($10) targets is unusually wide for a stock of this size — the Street is genuinely split on whether Nu's margin expansion story justifies the re-rating the stock has already had. Factor scores underscore the ambiguity: EPS momentum over both 30 and 90 days ranks in the top 15% of the universe, yet EPS surprise comes in at just the 18th percentile, meaning estimates are running ahead of actual beats. Analyst recommendation divergence ranks at the 92nd percentile — a statistical way of saying the Street has rarely been this split on Nu.
Options positioning has turned more cautious than usual, and that shift intensified this week. The put/call ratio reached 0.57 on Tuesday — more than two standard deviations above its 20-day average of 0.50, the most defensive tilt in roughly six weeks. For context, Nu spent most of June with the PCR comfortably below 0.48; the move higher is abrupt rather than gradual. With earnings due August 6, the hedging reads as deliberate pre-event protection rather than directional bearishness. History gives traders reason for caution: the February print saw the stock fall nearly 9% the next day and lose another point over the following week. The May result was kinder — down 4.9% on the day but recovering 2.7% by day five. Neither reaction was painless.
The lending market pushes back hard against any bearish read. Borrow availability is extraordinarily loose at roughly 2,020% — meaning there are about twenty shares available for every one currently lent out. That figure has actually tightened from over 6,000% in mid-June, reflecting a steady build in short interest, but remains far above any level that would signal squeeze pressure. Cost to borrow has eased about 8% over the week to just 0.38%, a historically cheap level for this name. Short interest at 4.1% of free float is manageable — it has crept up roughly 3% on the week, but the absolute level is not alarming. The ORTEX short score of 36.6 ranks in the 32nd percentile, consistent with a stock where shorts are present but not pressing hard.
Institutional ownership adds a constructive undertone. BlackRock added 38 million shares as of June 30, lifting its stake to roughly 7% of shares outstanding. Lone Pine and Jennison both added meaningfully in the most recent filings — hedge fund and active manager accumulation that typically signals conviction on the growth thesis rather than passive index rebalancing. Insider activity cuts the other way: the CFO, CEO David Velez, and co-founder Cristina Junqueira all sold in April, and Junqueira sold over $4 million worth in March. The trades were routine-sized relative to the cap table, but the cluster of executive selling near the $14–$15 level is worth noting given the stock is back in that range.
The August 6 print will clarify which side of the analyst divide is right — whether Nu's credit quality and customer acquisition in Mexico are tracking ahead of consensus, or whether the Citi and BofA downgrades were early reads on a deceleration that the bulls have not yet priced in.
See the live data behind this article on ORTEX.
Open NU on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
